BC Platforms and Microsoft to Provide Expanded Genomic Data Management Solutions in the Cloud
News Mar 03, 2016
BC Platforms has announced that it will collaborate with Microsoft to use the Microsoft Azure cloud platform and services to provide integrated genomic data management solutions in healthcare. Microsoft Corp. and BC Platforms will build the first proof of concept case with Helsinki University Hospital in 2016.
“Microsoft is the first cloud provider recognized by the European Union’s data protection authorities for the commitment of rigorous EU privacy laws, which is one of the main reasons BC Platforms decided to implement our computing and analytics on Microsoft Azure,” Tero Silvola, CEO of BC Platforms commented on the collaboration.
With this collaboration, BC Platforms can bring more new customers on board with the confidence that the solution can be rapidly up-scaled as needed.
“With Microsoft Azure, we don’t have to worry about setting up additional infrastructure or whether we can sustain growth with the current capacity in our data centers. Instead, we can seamlessly connect our current infrastructure with cloud,” says Chief Architect Timo Kanninen at BC Platforms.
”We are delighted to be providing these genomics solutions on Microsoft Azure, in collaboration with BC Platforms. Together, we can provide a complete platform for the interpretation of complex genomic and clinical data across key international markets,” said David Heckerman, distinguished scientist at Microsoft.
IT Director, Mikko Rotonen from University Hospital Helsinki commented: “Microsoft and BC Platforms are committed to the integration of genomic data, alongside clinical data, to provide the best health outcomes for patients. We are pleased to be working with both companies to tackle the major challenges that we currently face in translating this data into clinical benefits.”
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE